Wordt geladen...
Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage
BACKGROUND: Phase I/II placebo-controlled clinical trials of recombinant Factor VIIa (rFVIIa) suggested that administration of rFVIIa within 4 hours after onset of intracerebral hemorrhage (ICH) is safe, limits ICH growth, and improves outcomes. We sought to determine the cost-effectiveness of rFVII...
Bewaard in:
| Hoofdauteurs: | , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2008
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2397434/ https://ncbi.nlm.nih.gov/pubmed/18489750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-8-17 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|